CN111133102B - 生产重组病毒的方法 - Google Patents

生产重组病毒的方法 Download PDF

Info

Publication number
CN111133102B
CN111133102B CN201880038591.8A CN201880038591A CN111133102B CN 111133102 B CN111133102 B CN 111133102B CN 201880038591 A CN201880038591 A CN 201880038591A CN 111133102 B CN111133102 B CN 111133102B
Authority
CN
China
Prior art keywords
seq
certain embodiments
oncolytic adenovirus
recombinant
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880038591.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111133102A (zh
Inventor
托尼·R·雷德
布莱恩·T·奥兰斯基
克里斯托弗·拉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epicentrx Inc
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Publication of CN111133102A publication Critical patent/CN111133102A/zh
Application granted granted Critical
Publication of CN111133102B publication Critical patent/CN111133102B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880038591.8A 2017-04-10 2018-04-10 生产重组病毒的方法 Active CN111133102B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483837P 2017-04-10 2017-04-10
US62/483,837 2017-04-10
PCT/US2018/026977 WO2018191313A1 (en) 2017-04-10 2018-04-10 Method for producing recombinant virus

Publications (2)

Publication Number Publication Date
CN111133102A CN111133102A (zh) 2020-05-08
CN111133102B true CN111133102B (zh) 2024-08-16

Family

ID=63792776

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880038591.8A Active CN111133102B (zh) 2017-04-10 2018-04-10 生产重组病毒的方法

Country Status (8)

Country Link
US (2) US11999973B2 (enExample)
EP (1) EP3610003A4 (enExample)
JP (2) JP7229173B2 (enExample)
KR (2) KR20240032169A (enExample)
CN (1) CN111133102B (enExample)
AU (1) AU2018253088B2 (enExample)
CA (1) CA3059605A1 (enExample)
WO (1) WO2018191313A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3610003A4 (en) * 2017-04-10 2021-01-06 EpicentRx, Inc. RECOMBINANT VIRUS PRODUCTION PROCESS
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
CN111793595A (zh) * 2020-07-23 2020-10-20 上海奥浦迈生物科技有限公司 一种hek293细胞无血清培养基
EP4554559A1 (en) 2022-07-13 2025-05-21 EpicentRx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032754A1 (en) * 1998-12-01 2000-06-08 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
WO2005063970A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
WO2010101921A2 (en) * 2009-03-02 2010-09-10 The Regents Of The University Of California Tumor-selective e1a and e1b mutants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039459A2 (en) 2001-11-05 2003-05-15 Genvec, Inc. Viral vector production methods and compositions
JP4301558B2 (ja) * 2003-12-26 2009-07-22 日東電工株式会社 偏光板用接着剤、偏光板、その製造方法、光学フィルムおよび画像表示装置
US20190352669A1 (en) * 2017-01-30 2019-11-21 Epicentrx, Inc. Tumor selective tata-box and caat-box mutants
EP3610003A4 (en) * 2017-04-10 2021-01-06 EpicentRx, Inc. RECOMBINANT VIRUS PRODUCTION PROCESS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
WO2000032754A1 (en) * 1998-12-01 2000-06-08 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
WO2005063970A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
WO2010101921A2 (en) * 2009-03-02 2010-09-10 The Regents Of The University Of California Tumor-selective e1a and e1b mutants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E 1a and E1b;HEDJRAN, F ET AL;《CANCER GENE THERAPY》;20110805;第18卷;标题，摘要及第719页 *
Development of a serum-free suspension process for the production of a conditionally replicating adenovirus using A549 cells;LONGLEY;CYTOTECHNOLOGY;第49卷;第161 - 171页 *
Establishment and validation of new complementing cells for production of E1-deleted adenovirus vectors in serum-free suspension culture;RENALO GILBERT ET AL;《RENALO GILBERT ET AL》;20141101;第208卷;摘要、图1，第179 页左栏第2段，右栏第2段及最后1段、第 183 页左栏最后1段-右栏最后1段，第184页右栏第1段、图2、7，第178页左栏倒数第二段，182 页右栏第1段，第185页左栏第2段，第186页右栏倒数第2段、第180页左栏第1段、第186页左栏第1段 *
LONGLEY.Development of a serum-free suspension process for the production of a conditionally replicating adenovirus using A549 cells.CYTOTECHNOLOGY.2005,第49卷第161 - 171页. *

Also Published As

Publication number Publication date
US12291726B2 (en) 2025-05-06
WO2018191313A1 (en) 2018-10-18
KR20200004313A (ko) 2020-01-13
JP2023053298A (ja) 2023-04-12
US20240294883A1 (en) 2024-09-05
JP2020516277A (ja) 2020-06-11
JP7229173B2 (ja) 2023-02-27
AU2018253088B2 (en) 2024-09-19
EP3610003A4 (en) 2021-01-06
US20200032223A1 (en) 2020-01-30
EP3610003A1 (en) 2020-02-19
KR20240032169A (ko) 2024-03-08
AU2018253088A1 (en) 2019-11-28
CN111133102A (zh) 2020-05-08
KR102643016B1 (ko) 2024-02-29
US11999973B2 (en) 2024-06-04
CA3059605A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
CN111133102B (zh) 生产重组病毒的方法
US12036247B2 (en) Multiple transgene recombinant adenovirus
US20190352616A1 (en) Multiple transgene recombinant adenovirus
EP3573632B1 (en) Tumor selective tata-box and caat-box mutant oncolytic viruses
JP2022513639A (ja) 低神経毒性ｈｓｖベクター
US20250388930A1 (en) Tumor selective tata-box and caat-box mutants
WO2025129693A1 (en) Recombinant oncolytic herpes virus having an oxygen dependent degradation domain
HK40018033B (en) Tumor selective tata-box and caat-box mutant oncolytic viruses
HK40018033A (en) Tumor selective tata-box and caat-box mutant oncolytic viruses
WO2024251286A1 (zh) 溶瘤性hsv-1临床分离株、定向进化株、感染性克隆及应用
EP4469587A1 (en) Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant